Compositions and methods for rapid and reversible biomolecular labeling
US-2024426816-A1 · Dec 26, 2024 · US
Markers for dopaminergic neuron progenitor cells
US9453840B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9453840-B2 |
| Application number | US-201214234361-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 27, 2012 |
| Priority date | Jul 27, 2011 |
| Publication date | Sep 27, 2016 |
| Grant date | Sep 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3gal6, Slc39a12, Tacr1, Lrtm1, Dscam and CD201.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for producing dopaminergic neuron progenitor cells, said method comprising: (i) inducing a cell population comprising dopaminergic neuron progenitor cells from pluripotent stem cells; and (ii) extracting from the cell population cells expressing Lrtm1, wherein cells expressing Lrtm1 are extracted from the cell population by contacting the cell population with one or more reagents having specific affinity to Lrtm1 and extracting cells that bind to the one or more reagents having specific affinity to Lrtm1, and wherein the extracted cells comprise dopaminergic neuron progenitor cells. 2. The method according to claim 1 , further comprising extracting corin and/or Lmx1a positive cells from the cells extracted in step (ii), wherein cells expressing corin and/or Lmx1a are extracted from the cell population by contacting the cell population with one or more reagents having specific affinity to corin and/or Lmx1a and extracting cells that bind to the one or more reagents. 3. The method according to claim 1 , wherein said dopaminergic neuron progenitor cells are human dopaminergic neuron progenitor cells. 4. The method according to claim 1 , wherein said cell population is induced from pluripotent stem cells by culturing the pluripotent stem cells in a medium supplemented with a BMP inhibitor and a TGFβ inhibitor in step (i). 5. The method according to claim 1 , wherein cells expressing Lrtm1 are extracted from the cell population by contacting the cell population with one or more antibodies that bind to Lrtm1 and extracting cells that bind to the one or more antibodies. 6. A method for enriching dopaminergic neuron progenitor cells, said method comprising: (i) providing a cell population comprising dopaminergic neuron progenitor cells, wherein the cell population is induced from pluripotent stem cells or the cell population is composed of cells of an isolated tissue or tissues; and (ii) extracting from the cell population cells expressing Lrtm1, wherein cells expressing Lrtm1 are extracted from the cell population by contacting the cell population with one or more reagents having specific affinity to Lrtm1 and extracting cells that bind to the one or more reagents, and wherein the extracted cells comprise dopaminergic neuron progenitor cells. 7. The method according to claim 6 , wherein cells expressing Lrtm1 are extracted from the cell population by contacting the cell population with one or more antibodies that bind to Lrtm1 and extracting cells that bind to the one or more antibodies.
Assignees
Inventors
Classifications
from embryonic cells · CPC title
Stem cells · CPC title
Activin; Inhibin; Mullerian inhibiting substance · CPC title
Bone marrow stromal cells; whole marrow · CPC title
Kinases (EC 2.7.) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9453840B2 cover?
- The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm…
- Who is the assignee on this patent?
- Takahashi Jun, Doi Daisuke, Samata Bumpei, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/56966. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).